FLAURA

Osimertinib in Untreated EGFR-Mutated Advanced NSCLC

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 556 patients with untreated EGFR-mutated advanced NSCLC, osimertinib improved progression-free and overall survival compared with first-generation EGFR-TKI (gefitinib or erlotinib).

556

Schéma

Double-blind RCT

Critère

Progression-free survival

Pertinence

RésultatPFS 18.9 vs 10.2 months (HR 0.46). OS 38.6 vs 31.8 months (HR 0.80).

Soria JC, et al. N Engl J Med. 2018;378(2):113-125; Ramalingam SS, et al. N Engl J Med. 2020;382(1):41-50. 10.1056/NEJMoa1713137

Discussion et critique

Established osimertinib as first-line standard in EGFR-mutated NSCLC; superseded by FLAURA2 (osimertinib + chemo) in fit patients with high-risk features.